LENSAR, Inc. (LNSR)

3.4300 +0.1700 (+5.21%) At close: 04:00PM EDT

LENSAR, Inc.

2800 Discovery Drive
Orlando, FL 32826
United States
888 536 7271
https://www.lensar.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 130

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nicholas T. Curtis	President, CEO & Director	974.29k	N/A	1957
Mr. Thomas R. Staab II, CPA	CFO & Secretary	612.55k	N/A	1968
Mr. Alan B. Connaughton	Chief Operating Officer	650.62k	N/A	1972
Ms. Kendra W. Wong	Principal Accounting Officer	N/A	N/A	1980

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Corporate governance

LENSAR, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.